

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7359750/l-l-ding-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35 papers	100 citations	6 h-index	9 g-index
35 ext. papers	194 ext. citations	3.5 avg, IF	3.72 L-index

#	Paper	IF	Citations
35	Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials. <i>Primary Care Diabetes</i> , 2021 , 15, 208-211	2.4	11
34	SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. <i>Pharmacological Research</i> , 2020 , 161, 105175	10.2	9
33	Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). <i>Menopause</i> , 2019 , 26, 929-939	2.5	9
32	GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. <i>Diabetes Therapy</i> , 2020 , 11, 2429-2440	3.6	8
31	Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Diabetes and Vascular Disease Research</i> , 2021 , 18, 14791641211011016	3.3	8
30	Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. <i>Osteoporosis International</i> , 2020 , 31, 961-971	5.3	7
29	Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. <i>Endocrine</i> , 2020 , 69, 688-691	4	5
28	Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
27	Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e23489	1.8	4
26	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis. <i>PLoS ONE</i> , 2020 , 15, e0234123	3.7	4
25	Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. <i>Medicine (United States)</i> , 2021 , 100, e25121	1.8	4
24	Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 77, 34-37	3.1	4
23	Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Endocrine</i> , 2021 , 73, 31-36	4	4
22	Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105799	2.8	3
21	Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. <i>Endocrine Journal</i> , 2021 , 68, 739-742	2.9	3
20	Impact of time factor and patient characteristics on the efficacy of PCI vs CABG for left main coronary disease: A meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e25057	1.8	2
19	Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?. <i>European Journal of Internal Medicine</i> , 2021 , 87, 98-99	3.9	2

18	Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107803	3.2	2
17	Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021 , 12, 664502	5.7	1
16	Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 699-706	2.6	1
15	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 690529	5.4	1
14	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	1
13	Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF. <i>ESC Heart Failure</i> , 2021 , 8, 1722-1724	3.7	1
12	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials. <i>Medicine (United States)</i> , 2021 , 100, e27362	1.8	1
11	Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs. <i>Clinical Respiratory Journal</i> , 2021 , 15, 847-850	1.7	0
10	Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures. <i>Medicine (United States)</i> , 2020 , 99, e22690	1.8	
9	Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis". <i>Heart Failure Reviews</i> , 2021 , 1	5	
8	SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF. <i>European Journal of Internal Medicine</i> , 2021 , 87, 102-103	3.9	
7	Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 1077-1078	3.9	
6	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		
5	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		
4	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		
3	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		
2	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		
1	Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis 2020 , 15, e0234123		

